"First to Complete Full Lineup of PFS and AI Formulations"
Targeting the North American Market with Enhanced Product Competitiveness

Celltrion announced on January 29 that it has received additional approval from Health Canada for its chronic spontaneous urticaria treatment, Omiclo (active ingredient: omalizumab), in both the 300mg pre-filled syringe (PFS) and 300mg auto-injector (AI) formulations.

The newly approved PFS and AI formulations are high-dose 300mg products, capable of delivering a sufficient amount of medication with a single administration. This reduces the frequency of dosing, lessening the burden on patients and broadening the range of prescription options available to healthcare professionals.

Celltrion stated, "With this approval, we have secured the entire lineup of PFS and AI formulations (75mg, 150mg, and 300mg) originally held by the reference biologic in Canada. This marks the first case among omalizumab biosimilars in the global market to complete the full range of PFS and AI formulations."

Omiclo is an omalizumab biosimilar used to treat various allergic conditions, including chronic spontaneous urticaria and asthma. After obtaining first-mover approvals in major global markets such as the United States, Europe, Canada, and South Korea, the product is being launched sequentially. As of 2024, the original drug, Xolair, recorded global sales of approximately 6.4992 trillion KRW.

Canada is a leading country where the government actively encourages biosimilar prescriptions. Products that offer the same range of formulations as the original biologic can secure a competitive advantage. Based on its strengthened product competitiveness, Celltrion plans to accelerate its expansion in the North American market.

A Celltrion representative commented, "By securing the entire lineup of PFS and AI formulations in the market, we are now able to provide tailored prescriptions for various patient cases. We will do our utmost to expand our presence in the North American market, with a focus on Canada, leveraging our enhanced product competitiveness."



This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing